Boulder, Colorado-based Array BioPharma announced this morning that it has initiated a Phase 1 clinical trial for its small molecule drug for the treatment of inflammatory disease. The biotech firm said that its compound, ARRY-438162, will be evaluated in dose escalation studies in healthy volunteers. Array said that it believes its new, proprietary molecule will be useful in treating acute and chronic inflammatory diseases, including rheumatoid arthritis, chronic obstructive pulmonary disease and inflammatory bowel disease.
Top NewsWednesday, April 26, 2006
Array BioPharma Enters Phase 1